chenodeoxycholic acid has been researched along with Cholangiocarcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, AH; Atkinson, EJ; Eaton, JE; Hu, C; Iyer, RK; Juran, BD; Lazaridis, KN; McCauley, BM | 1 |
| Adorini, L; Andersen, JB; Arbelaiz, A; Banales, JM; Bujanda, L; Caro-Maldonado, A; Carracedo, A; Erice, O; Gómez-Vallejo, V; Jimenez-Agüero, R; Labiano, I; Llop, J; Lozano, E; Marin, JJ; Martin, A; Martín-Martín, N; Marzioni, M; Munoz-Garrido, P; O'Rourke, CJ; Olaizola, P; Padro, D; Perugorria, MJ; Santos-Laso, A; Trauner, M | 1 |
| Adorini, L; Alvaro, D; Berloco, PB; Bragazzi, M; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Gaudio, E; Giorgi, A; Giuliante, F; Giulitti, F; Grazi, G; Manzi, E; Melandro, F; Napoletano, C; Nevi, L; Overi, D; Safarikia, S | 1 |
| Chen, W; Chu, H; Hou, Z; Huang, Q; Li, Q; Man, M; Wang, J; Wang, W; Zhan, M | 1 |
| Abe, T; Egawa, S; Fukase, K; Ii, T; Katayose, Y; Motoi, F; Mutoh, M; Ohtsuka, H; Oikawa, M; Onogawa, T; Oshio, H; Rikiyama, T; Unno, M | 1 |
5 other study(ies) available for chenodeoxycholic acid and Cholangiocarcinoma
| Article | Year |
|---|---|
Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data.
Topics: Artificial Intelligence; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chenodeoxycholic Acid; Cholangiocarcinoma; Cholangitis, Sclerosing; Humans; Inflammatory Bowel Diseases; Sexually Transmitted Diseases | 2023 |
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Topics: Aged; Aged, 80 and over; Animals; Bile Acids and Salts; Bile Duct Neoplasms; Bile Ducts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chenodeoxycholic Acid; Cholangiocarcinoma; Cholic Acids; Cohort Studies; Disease Progression; Energy Metabolism; Epithelial Cells; Female; Gastrointestinal Agents; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitochondria; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Xenograft Model Antitumor Assays | 2018 |
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Topics: Animals; Apoptosis; Bile Duct Neoplasms; Cell Movement; Cell Proliferation; Chenodeoxycholic Acid; Cholangiocarcinoma; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Receptors, Cytoplasmic and Nuclear; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Biliary Tract; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chenodeoxycholic Acid; Cholangiocarcinoma; Cisplatin; Down-Regulation; Drug Synergism; Frataxin; Gallbladder Neoplasms; Humans; Iron-Binding Proteins; Isoxazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT3 Transcription Factor | 2016 |
Bile acids repress E-cadherin through the induction of Snail and increase cancer invasiveness in human hepatobiliary carcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chenodeoxycholic Acid; Cholangiocarcinoma; Down-Regulation; Female; Gastrointestinal Agents; Humans; Lithocholic Acid; Liver Neoplasms; Male; Neoplasm Invasiveness; Snail Family Transcription Factors; Transcription Factors | 2008 |